/ /

Wayne Kuznar
Study: Active surveillance uptake remains low
The overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.
IC/BPS: One-fourth of patients have Hunner lesions
About one-fourth of patients with interstitial cystitis/bladder pain syndrome have Hunner lesions in the bladder visible on cystoscopy.
Repeat hydrodistention found safe in treating IC
Repeated hydrodistention as therapy for interstitial cystitis has a low complication rate and does not decrease bladder capacity over time.
Genomic testing linked to higher surveillance uptake
In men with clinically low-risk prostate cancer managed in community-based urology practices, utilization of active surveillance as initial management is higher among those who undergo genomic testing.
CCP score further risk stratifies surveillance candidates
Use of a cell cycle progression genomics test (Prolaris) can further stratify risk in men who are candidates for active surveillance based on clinical criteria, and therefore may have a role in decision-making in men with early-stage prostate cancer, researchers say.
Single-use scope yields 45-min average surgery time
Flexible ureteroscopy using a digital single-use flexible ureteroscope known as PUSEN achieves stone-free rates on par with reusable flexible ureteroscopes, with a total surgery time averaging 45 minutes.
Two-drug therapy for advanced UC shows superior PFS
Adding ramucirumab (CYRAMZA) to standard docetaxel (Taxotere) improved progression-free survival compared with docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.
Single-use ureteroscope shows efficacy for routine URS
A new single-use digital flexible ureteroscope (LithoVue) compares favorably in performance to reusable scopes, at least for routine urteroscopy, with a possible advantage of being more economical.
5-ARI use does not raise erectile dysfunction risk
The risk of erectile dysfunction is not increased with the use of a 5-alpha-reductase inhibitor compared with an alpha-blocker for the treatment of BPH.
Urologists no longer primary initiator of tamsulosin
Urologists are no longer the primary initiators of tamsulosin (Flomax) therapy in the United States, suggests an analysis of pharmaceutical claims from more than 50 private health plans.

Poll

View Results